Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.61 |
| ▸ | CTSL | P07711 | 1/20 | 0.61 |
| ▸ | CTSB | P07858 | 1/20 | 0.61 |
| ▸ | CTSS | P25774 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | MME | P08473 | 1/20 | 0.59 |
| ▸ | ECE1 | P42892 | 1/20 | 0.59 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.57 |
| ▸ | ELANE | P08246 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL241565 | 1.00 | CTSK (0.61) | CTSKCTSLCTSBCTSSATM | |
| SCHEMBL241564 | 1.00 | CTSK (0.61) | CTSKCTSLCTSBCTSSATM | |
| Hydrochloric Acid SCHEMBL7400995 | 0.98 | CTSK (0.60) | CTSKCTSLCTSBCTSSATM | |
| Hydrochloric Acid SCHEMBL7400990 | 0.98 | CTSK (0.60) | CTSKCTSLCTSBCTSSATM | |
| SCHEMBL8177898 | 0.94 | CTSK (0.62) | CTSKCTSLCTSBCTSSATM | |
| Glycolic Acid SCHEMBL901392 | 0.94 | CTSK (0.56) | CTSKCTSLCTSBCTSSATM | |
| SCHEMBL22475275 | 0.94 | CTSK (0.62) | CTSKCTSLCTSBCTSSATM | |
| SCHEMBL7421757 | 0.94 | CTSK (0.62) | CTSKCTSLCTSBCTSSATM | |
| SCHEMBL10954146 | 0.94 | CTSK (0.62) | CTSKCTSLCTSBCTSSATM | |
| Alanine SCHEMBL11300392 | 0.94 | CTSK (0.56) | CTSKCTSLCTSBCTSSATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 370 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3988538-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | claimed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | claimed |
| CN-112110834-A | Modified hydrophobic auxiliary material and preparation method and application thereof | 浙江智达药业有限公司 | 2020-12-22 | — | — | CN | claimed |
| EP-0118105-A2 | 2-Cyanosteroids | G.D. Searle & Co. (US) | 1984-09-12 | — | — | EP | claimed |
| US-4459235-A | 2-Cyanosteroids | G. D. SEARLE & CO. (US) | 1984-07-10 | — | — | US | claimed |
| JP-57028099-A | — | — | None | — | — | JP | disclosed |
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| EP-4692089-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AS AAK1 INHIBITOR | Alicorn Pharmaceutical Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| EP-4656201-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250360205-A1 | NOD1 MODULATORS AND USES THEREOF | ACADEMIA SINICA (TW) | 2025-11-27 | — | — | US | disclosed |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. | 2025-06-19 | — | — | US | disclosed |
| CN-120058739-A | Cycloalkyl-or haloalkyl-containing compounds | 正大天晴药业集团股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-4174312-A | ACYLATION, HYDROLYSIS, SALT FORMATION, CATALYTIC HYDROGENATION | ABBOTT LABORATORIES (US) | 1979-11-13 | — | — | US | disclosed |
| US-4173564-A | 4-N-acylfortimicin B derivatives and the chemical conversion of fortimicin B to fortimicin A | ABBOTT LABORATORIES (US) | 1979-11-06 | — | — | US | disclosed |
| EP-0002039-A1 | Phosphonous acid derivatives, processes for their preparation and their use in combating microorganisms | CIBA-GEIGY AG (CH) | 1979-05-30 | — | — | EP | disclosed |
| US-4155902-A | ACYLATION, HYDROGENOLYSIS | ABBOTT LABORATORIES (US) | 1979-05-22 | — | — | US | disclosed |
| US-4091032-A | ANTIMICROBIAL AGENTS | ABBOTT LABORATORIES (US) | 1978-05-23 | — | — | US | disclosed |
| US-4087520-A | Lowering blood pressure with new L-3-(3,4-dihydroxyphenyl)-2-methyl-alanine peptides | BOEHRINGER MANNHEIM GMBH (DT) | 1978-05-02 | — | — | US | disclosed |
| US-4012367-A | Anti-ulcer polypeptides containing L-aspartic acid and intermediates thereto | G. D. SEARLE & CO. (US) | 1977-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | CETP, LIPA, MTTP | CTSK 2251/4885CTSL 1366/4885CTSB 1304/4885 |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | SOS1, PPM1D, PTPN1 | CTSK 3524/4885CTSL 4005/4885CTSB 3608/4885 |
| US-20250360205-A1 | NOD1 MODULATORS AND USES THEREOF | NOD1, TLR1, NOD2 | CTSK 4192/4885CTSL 3108/4885CTSB 2745/4885 |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | CETP, SLC43A1, SLC27A1 | CTSK 4188/4885CTSL 1811/4885CTSB 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.